ClinicalTrials.gg
CompletedNCT01376245Updated Jan 11, 2017Results posted

A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD

A Phase 3 interventional study of fluticasone furoate/vilanterol and Placebo in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 34 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-01-11.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
646
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. fluticasone furoate · Pulmonary Disease, Chronic Obstructive.

Enrollment
8th of 25
646 · median 229
Started
2011
with 3 others
Phase 3
7 of 25
none open now
Registered
5th of 25
by date
Lead sponsor
21 of 25
GlaxoSmithKline

Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, this one is the 8th largest by enrollment, is one of 4 that started in 2011, is one of 7 in phase 3, and was the 5th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of the study is to investigate the efficacy and safety of fluticasone furoate/vilanterol Inhalation Powder compared with placebo over a 24 weeks treatment period in subjects of Asian ancestry with Chronic Obstructive Pulmonary Disease (COPD).

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis define by ATS(American Thoracic Society)/ ERS (European Respiratory Society)
  • Subjects of Asian ancestry
  • Valid
  • Current or former smoker
  • > or = 2 on the modified Medical Research Council Dyspnea Scale at Screening

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • A current diagnosis of asthma
  • alpha1-antitrypsin deficiency as the underlying cause for
  • Other active, respiratory disorders
  • Have lung volume reduction surgery within 12 months prior to Screening
  • A chest X-ray or CT (Computerised Tomography) scan reveals evidence of clinical significant abnormalities not believed to be due to the presence of COPD
  • Poorly controlled COPD: acute worsening of COPD managed by , antibiotics, or treatments prescribed by a physician 6 weeks prior to Screening, or requires hospitalisation due to poorly controlled COPD 12 weeks prior to Screening
  • Lower respiratory tract infection requires antibiotics within 4 weeks prior to Screening
  • Other disease or abnormalities, in the opinion of the investigator, would put the safety of the subject at risk during the study or would affect safety or efficacy analysis if the disease/condition exacerbated during the study
  • Subject with carcinoma that has not been in complete remission for at least 5 years, carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded if the subject has been considered cured within 5 years since diagnosis.
  • Subject has a history of to any of the study medications or components of the inhalation powder. Subject has a history of severe milk protein allergy that, in the opinion of the investigator, contraindicates the subject's participation will also be excluded.
  • Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years prior to Screening
  • Subjects who are medically unable to withhold albuterol, ipratropium for 4 hrs and/or theophylline for 12 hrs prior to spirometry testing.
  • Subjects use a list of prohibited medications specified in the study protocol, including but not limited to traditional or herbal medications for the treatment of COPD
  • Subject requires long-term oxygen therapy or nocturnal oxygen therapy for greater than 12 hours a day
  • Pulmonary rehabilitation: subjects who are in the maintenance phase are not excluded.
  • Non-compliance
  • Questionable validity of the
  • Prior use of study medication or other drugs
  • Affiliation with investigator site
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
646 participants (actual)

Study arms

  • Experimental
    fluticasone furoate/vilanterol

    Inhaled corticosteroid/long acting beta-agonist

    Drug: fluticasone furoate/vilanterol

  • Placebo comparator
    placebo

    matching placebo

    Drug: Placebo

Interventions

  • Drugfluticasone furoate/vilanterol

    Drug pages: Fluticasone furoate · Vilanterol

    Inhaled corticosteroid/long acting beta-agonist

  • DrugPlacebo

    matching placebo

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Clinic Visit Pre-dose Trough FEV1 at Day 169

    Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 was defined as the pre-dose and pre-bronchodilator FEV1, which was obtained at each clinic visit. Baseline is defined as the mean of the two assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.Trough FEV1 is defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing at each clinic visit. Change from Baseline was calculated as the average at each clinic visit minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, smoking status at screening (stratum), baseline - mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1, day, day by baseline and day by treatment interactions.

    Time frame: Baseline to Day 169

Secondary outcomes

  1. Mean Change From Baseline in Chronic Respiratory Disease Questionnaire Self-administered Standardized (CRQ-SAS) Dyspnea Domain Score at Day 168

    CRQ-SAS measures 4 domains (fatigue, emotional function, mastery and dyspnea) of functioning of participants (par.) with COPD: mastery (amount of control the par. feels he/she has over COPD symptoms); fatigue (how tired the par. feels); emotional function (how anxious/depressed the par. feels); and dyspnea (how short of breath the par. feels during physical activities). Each domain is calculated separately and measured on a scale of 1-7 (1=maximum impairment; 7=no impairment). Dyspnea domain score is the mean of all non-missing responses for that domain. Only the dyspnea domain was measured as a secondary outcome. BL scores are the derived scores for each domain and total at Day 1 pre-dose. Change from BL was calculated as the average of the Day 168 values minus the BL value. Analysis performed used a repeated measures model with covariates of treatment, smoking status at screening (stratum), BL (derived scores at Day 1 pre-dose), day, day by BL, and day by treatment interactions.

    Time frame: Baseline (BL) and Day 168

07

Results

Posted Jan 28, 2014

Participant flow

2-wk Single-blind Placebo Run-in Period
Participant flow — 2-wk Single-blind Placebo Run-in Period
MilestonePlacebo- Run-inPlaceboFF /VI 50/25 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg OD
Started7440000
Completed6430000
Not completed1010000
Withdrew: Did not meet continuation criteria660000
Withdrew: Adverse event40000
Withdrew: Lost to follow-up10000
Withdrew: Physician decision20000
Withdrew: Withdrawal by subject280000
24-week, Double-blind Treatment Period
Participant flow — 24-week, Double-blind Treatment Period
MilestonePlacebo- Run-inPlaceboFF /VI 50/25 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg OD
Started0162160161160
Completed0130135138134
Not completed032252326
Withdrew: Adverse event0167818
Withdrew: Lack of efficacy04543
Withdrew: Protocol violation02021
Withdrew: Met protocol-defined stopping criteria02310
Withdrew: Lost to follow-up02011
Withdrew: Physician decision00110
Withdrew: Withdrawal by subject06963

Outcome measures

PrimaryMean Change From Baseline in Clinic Visit Pre-dose Trough FEV1 at Day 169

Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 was defined as the pre-dose and pre-bronchodilator FEV1, which was obtained at each clinic visit. Baseline is defined as the mean of the two assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.Trough FEV1 is defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing at each clinic visit. Change from Baseline was calculated as the average at each clinic visit minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, smoking status at screening (stratum), baseline - mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1, day, day by baseline and day by treatment interactions.

Time frame:
Baseline to Day 169
Reported as:
Least squares mean · Liters
Mean Change From Baseline in Clinic Visit Pre-dose Trough FEV1 at Day 169
LitersPlaceboFF/VI 50/25 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg OD
Mean Change From Baseline in Clinic Visit Pre-dose Trough FEV1 at Day 169-0.027 ± 0.01840.113 ± 0.01830.152 ± 0.01810.167 ± 0.0182
Statistical analysis
  • Placebo vs FF/VI 50/25 µg OD · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.140 · 95% CI 0.089 to 0.191Restricted Maximum Likelihood (REML)-based repeated measures approach (MMRM)
  • Placebo vs FF/VI 100/25 µg OD · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.179 · 95% CI 0.129 to 0.230Restricted Maximum Likelihood (REML)-based repeated measures approach (MMRM)
  • Placebo vs FF/VI 200/25 µg OD · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.194 · 95% CI 0.143 to 0.245Restricted Maximum Likelihood (REML)-based repeated measures approach (MMRM)
SecondaryMean Change From Baseline in Chronic Respiratory Disease Questionnaire Self-administered Standardized (CRQ-SAS) Dyspnea Domain Score at Day 168

CRQ-SAS measures 4 domains (fatigue, emotional function, mastery and dyspnea) of functioning of participants (par.) with COPD: mastery (amount of control the par. feels he/she has over COPD symptoms); fatigue (how tired the par. feels); emotional function (how anxious/depressed the par. feels); and dyspnea (how short of breath the par. feels during physical activities). Each domain is calculated separately and measured on a scale of 1-7 (1=maximum impairment; 7=no impairment). Dyspnea domain score is the mean of all non-missing responses for that domain. Only the dyspnea domain was measured as a secondary outcome. BL scores are the derived scores for each domain and total at Day 1 pre-dose. Change from BL was calculated as the average of the Day 168 values minus the BL value. Analysis performed used a repeated measures model with covariates of treatment, smoking status at screening (stratum), BL (derived scores at Day 1 pre-dose), day, day by BL, and day by treatment interactions.

Time frame:
Baseline (BL) and Day 168
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in Chronic Respiratory Disease Questionnaire Self-administered Standardized (CRQ-SAS) Dyspnea Domain Score at Day 168
Scores on a scalePlaceboFF/VI 50/25 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg OD
Mean Change From Baseline in Chronic Respiratory Disease Questionnaire Self-administered Standardized (CRQ-SAS) Dyspnea Domain Score at Day 1680.09 ± 0.0810.30 ± 0.0800.43 ± 0.0790.37 ± 0.080

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study medication to the end of treatment (up to Week 24).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—14/162 (8.6%)27/162 (16.7%)
FF/VI 50/25 µg OD—9/160 (5.6%)33/160 (20.6%)
FF/VI 100/25 µg OD—7/161 (4.3%)34/161 (21.1%)
FF/VI 200/25 µg OD—14/160 (8.8%)40/160 (25%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventPlaceboFF/VI 50/25 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg OD
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders7/1623/1603/1618/160
PneumoniaInfections and infestations3/1622/1600/1612/160
Respiratory failureRespiratory, thoracic and mediastinal disorders0/1620/1600/1611/160
Acute myocardial infarctionCardiac disorders1/1621/1600/1610/160
Acute coronary syndromeCardiac disorders0/1620/1600/1611/160
Cardiac failure acuteCardiac disorders0/1620/1600/1611/160
Cardiac failure congestiveCardiac disorders0/1620/1600/1611/160
Burns third degreeInjury, poisoning and procedural complications0/1621/1600/1610/160
Head injuryInjury, poisoning and procedural complications0/1620/1600/1611/160
Cerebrovascular disorderNervous system disorders0/1620/1600/1611/160
Most frequent other events
Most frequent other events
EventPlaceboFF/VI 50/25 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg OD
NasopharyngitisInfections and infestations7/16213/1609/16119/160
Upper respiratory tract infectionInfections and infestations15/16216/16019/16114/160
CoughRespiratory, thoracic and mediastinal disorders2/1622/1606/1613/160
HypertensionVascular disorders1/1621/1602/1615/160
PyrexiaGeneral disorders5/1623/1604/1613/160

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboFF /VI 50/25 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg ODTotal
Mean64.7 ± 8.7865.2 ± 8.4165.1 ± 9.1962.7 ± 8.6564.4 ± 8.80
Gender
Gender(Participants)PlaceboFF /VI 50/25 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg ODTotal
Female1616121559
Male146144149145584
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboFF /VI 50/25 µg ODFF/VI 100/25 µg ODFF/VI 200/25 µg ODTotal
Asian - East Asian Heritage151149150148598
Asian - South East Asian1111111245
08

Study locations

34 sites
  • GSK Investigational Site
    Guangzhou, Guangdong 510120, China
  • GSK Investigational Site
    Guangzhou, Guangdong 510515, China
  • GSK Investigational Site
    Nanning, Guangxi 530021, China
  • GSK Investigational Site
    Changsha, Hunan 410011, China
  • GSK Investigational Site
    Shenyang, Liaoning 110001, China
  • GSK Investigational Site
    Shenyang, Liaoning 110015, China
  • GSK Investigational Site
    Xian, Shaanxi 710032, China
  • GSK Investigational Site
    Xian, Shaanxi 710061, China
  • GSK Investigational Site
    Hang Zhou, Zhejiang 310003, China
  • GSK Investigational Site
    Beijing, 100020, China
  • GSK Investigational Site
    Beijing, 100034, China
  • GSK Investigational Site
    Beijing, 100048, China
  • GSK Investigational Site
    Beijing, 100191, China
  • GSK Investigational Site
    Changsha, 410013, China
  • GSK Investigational Site
    Chengdu, 610041, China
  • GSK Investigational Site
    Chongqing, 400037, China
  • GSK Investigational Site
    Chongqing, 400038, China
  • GSK Investigational Site
    Shanghai, 200025, China
  • GSK Investigational Site
    Shanghai, 200080, China
  • GSK Investigational Site
    Shanghai, 200433, China
  • GSK Investigational Site
    Tianjin, 300052, China
  • GSK Investigational Site
    jeonju-si, Jeollabuk-Do, 561-712, Korea, Republic of
  • GSK Investigational Site
    Seoul, 158-710, Korea, Republic of
  • GSK Investigational Site
    Suwon, Gyeonggi-do, 442-723, Korea, Republic of
  • GSK Investigational Site
    Quezon City, 1100, Philippines
  • GSK Investigational Site
    Quezon City, 1109, Philippines
  • GSK Investigational Site
    Changhua, 500, Taiwan
  • GSK Investigational Site
    Kaohsiung, 833, Taiwan
  • GSK Investigational Site
    Taichung, 40201, Taiwan
  • GSK Investigational Site
    Taichung, 404, Taiwan
  • GSK Investigational Site
    Taichung, 40705, Taiwan
  • GSK Investigational Site
    Taipei, 100, Taiwan
  • GSK Investigational Site
    Taipei, 112, Taiwan
  • GSK Investigational Site
    Tau-Yuan County, 333, Taiwan
09

References and documents

Publications

  • Zheng J, de Guia T, Wang-Jairaj J, Newlands AH, Wang C, Crim C, Zhong N. Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Curr Med Res Opin. 2015 Jun;31(6):1191-200. doi: 10.1185/03007995.2015.1036016. PubMed 25830381 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2011
First posted
Jun 20, 2011
Start
Apr 2011
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results first posted
Jan 28, 2014
Last update
Jan 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01376245
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 20, 2011
Start date
Apr 2011
Primary completion
Sep 2012
Completion
Sep 2012
Results posted
Jan 28, 2014
Last update
Jan 11, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Vilanterol

Start the discussion